Is BLTE or INSM more profitable?

Belite Bio has a net margin of 0.00% compared to Insmed's net margin of -144.44%. Belite Bio's return on equity of -13.14% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Belite Bio N/A -13.14% -12.88% Insmed -144.44% -130.11% -51.57%

Does the media favor BLTE or INSM?

In the previous week, Insmed had 14 more articles in the media than Belite Bio. MarketBeat recorded 22 mentions for Insmed and 8 mentions for Belite Bio. Belite Bio's average media sentiment score of 1.07 beat Insmed's score of 1.07 indicating that Belite Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Belite Bio 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Insmed 12 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Is BNTX or BLTE more profitable?

Belite Bio has a net margin of 0.00% compared to BioNTech's net margin of -44.39%. BioNTech's return on equity of -5.30% beat Belite Bio's return on equity. Company Net Margins Return on Equity Return on Assets BioNTech -44.39% -5.30% -4.62% Belite Bio N/A -13.14% -12.88%

Does the media favor BNTX or BLTE?

In the previous week, BioNTech had 1 more articles in the media than Belite Bio. MarketBeat recorded 9 mentions for BioNTech and 8 mentions for Belite Bio. Belite Bio's average media sentiment score of 1.07 beat BioNTech's score of 0.97 indicating that Belite Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Belite Bio 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is BLTE or VTRS more profitable?

Belite Bio has a net margin of 0.00% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat Belite Bio's return on equity. Company Net Margins Return on Equity Return on Assets Belite Bio N/A -13.14% -12.88% Viatris -2.04% 19.04% 7.62%

Does the media favor BLTE or VTRS?

In the previous week, Belite Bio had 4 more articles in the media than Viatris. MarketBeat recorded 8 mentions for Belite Bio and 4 mentions for Viatris. Belite Bio's average media sentiment score of 1.07 beat Viatris' score of 0.47 indicating that Belite Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Belite Bio 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Viatris 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, GMAB or BLTE?

Genmab A/S has higher revenue and earnings than Belite Bio. Belite Bio is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genmab A/S $3.90B 4.61 $963M $1.32 21.87 Belite Bio N/A N/A -$77.61M -$2.53 N/A

Is GMAB or BLTE more profitable?

Genmab A/S has a net margin of 21.05% compared to Belite Bio's net margin of 0.00%. Genmab A/S's return on equity of 15.34% beat Belite Bio's return on equity. Company Net Margins Return on Equity Return on Assets Genmab A/S 21.05% 15.34% 8.94% Belite Bio N/A -13.14% -12.88%

Does the media refer more to GMAB or BLTE?

In the previous week, Belite Bio had 2 more articles in the media than Genmab A/S. MarketBeat recorded 8 mentions for Belite Bio and 6 mentions for Genmab A/S. Belite Bio's average media sentiment score of 1.07 beat Genmab A/S's score of 1.03 indicating that Belite Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genmab A/S 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Belite Bio 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor BLTE or ASND?

In the previous week, Belite Bio had 1 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 8 mentions for Belite Bio and 7 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 1.27 beat Belite Bio's score of 1.07 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Belite Bio 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ascendis Pharma A/S 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Belite Bio (BLTE) Competitors

$153.36 -2.92 (-1.87%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$153.10 -0.26 (-0.17%)

As of 07/24/2026 04:10 PM Eastern

Compare

BLTE vs. INSM, BNTX, VTRS, GMAB, and ASND

Should you buy Belite Bio stock or one of its competitors? MarketBeat compares Belite Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Belite Bio include Insmed (INSM), BioNTech (BNTX), Viatris (VTRS), Genmab A/S (GMAB), and Ascendis Pharma A/S (ASND). These companies are all part of the "pharmaceutical products" industry.

How does Belite Bio compare to Insmed?

Belite Bio (NASDAQ:BLTE) and Insmed (NASDAQ:INSM) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, media sentiment, dividends and risk.

Belite Bio has higher earnings, but lower revenue than Insmed. Belite Bio is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$77.61M	-$2.53	N/A
Insmed	$606.42M	38.22	-$1.28B	-$5.75	N/A

0.5% of Belite Bio shares are owned by institutional investors. 13.3% of Belite Bio shares are owned by insiders. Comparatively, 2.1% of Insmed shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Insmed had 14 more articles in the media than Belite Bio. MarketBeat recorded 22 mentions for Insmed and 8 mentions for Belite Bio. Belite Bio's average media sentiment score of 1.07 beat Insmed's score of 1.07 indicating that Belite Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Belite Bio	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Insmed	12 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Belite Bio presently has a consensus price target of $203.00, suggesting a potential upside of 32.37%. Insmed has a consensus price target of $209.13, suggesting a potential upside of 95.60%. Given Insmed's stronger consensus rating and higher probable upside, analysts plainly believe Insmed is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	2 Strong Buy rating(s)	3.00

Belite Bio has a beta of -1.23, meaning that its share price is 223% less volatile than the broader market. Comparatively, Insmed has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market.

Belite Bio has a net margin of 0.00% compared to Insmed's net margin of -144.44%. Belite Bio's return on equity of -13.14% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-13.14%	-12.88%
Insmed	-144.44%	-130.11%	-51.57%

Summary

Belite Bio and Insmed tied by winning 8 of the 16 factors compared between the two stocks.

How does Belite Bio compare to BioNTech?

BioNTech (NASDAQ:BNTX) and Belite Bio (NASDAQ:BLTE) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, media sentiment, institutional ownership, valuation and profitability.

In the previous week, BioNTech had 1 more articles in the media than Belite Bio. MarketBeat recorded 9 mentions for BioNTech and 8 mentions for Belite Bio. Belite Bio's average media sentiment score of 1.07 beat BioNTech's score of 0.97 indicating that Belite Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Belite Bio	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

15.5% of BioNTech shares are held by institutional investors. Comparatively, 0.5% of Belite Bio shares are held by institutional investors. 19.2% of BioNTech shares are held by company insiders. Comparatively, 13.3% of Belite Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

BioNTech presently has a consensus target price of $129.13, indicating a potential upside of 44.55%. Belite Bio has a consensus target price of $203.00, indicating a potential upside of 32.37%. Given BioNTech's higher possible upside, equities analysts clearly believe BioNTech is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74
Belite Bio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Belite Bio has lower revenue, but higher earnings than BioNTech. Belite Bio is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$2.81B	8.05	-$1.29B	-$5.88	N/A
Belite Bio	N/A	N/A	-$77.61M	-$2.53	N/A

Belite Bio has a net margin of 0.00% compared to BioNTech's net margin of -44.39%. BioNTech's return on equity of -5.30% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-44.39%	-5.30%	-4.62%
Belite Bio	N/A	-13.14%	-12.88%

BioNTech has a beta of 1.32, suggesting that its stock price is 32% more volatile than the broader market. Comparatively, Belite Bio has a beta of -1.23, suggesting that its stock price is 223% less volatile than the broader market.

Summary

BioNTech beats Belite Bio on 10 of the 15 factors compared between the two stocks.

How does Belite Bio compare to Viatris?

Belite Bio (NASDAQ:BLTE) and Viatris (NASDAQ:VTRS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends, media sentiment and risk.

0.5% of Belite Bio shares are owned by institutional investors. Comparatively, 79.9% of Viatris shares are owned by institutional investors. 13.3% of Belite Bio shares are owned by company insiders. Comparatively, 0.3% of Viatris shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Belite Bio has a net margin of 0.00% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-13.14%	-12.88%
Viatris	-2.04%	19.04%	7.62%

Belite Bio presently has a consensus target price of $203.00, suggesting a potential upside of 32.37%. Viatris has a consensus target price of $17.50, suggesting a potential upside of 1.51%. Given Belite Bio's stronger consensus rating and higher possible upside, research analysts clearly believe Belite Bio is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Viatris	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

Belite Bio has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than Belite Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$77.61M	-$2.53	N/A
Viatris	$14.56B	1.38	-$3.51B	-$0.26	N/A

Belite Bio has a beta of -1.23, meaning that its share price is 223% less volatile than the broader market. Comparatively, Viatris has a beta of 0.91, meaning that its share price is 9% less volatile than the broader market.

In the previous week, Belite Bio had 4 more articles in the media than Viatris. MarketBeat recorded 8 mentions for Belite Bio and 4 mentions for Viatris. Belite Bio's average media sentiment score of 1.07 beat Viatris' score of 0.47 indicating that Belite Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Belite Bio	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Viatris	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Belite Bio beats Viatris on 10 of the 16 factors compared between the two stocks.

How does Belite Bio compare to Genmab A/S?

Genmab A/S (NASDAQ:GMAB) and Belite Bio (NASDAQ:BLTE) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

In the previous week, Belite Bio had 2 more articles in the media than Genmab A/S. MarketBeat recorded 8 mentions for Belite Bio and 6 mentions for Genmab A/S. Belite Bio's average media sentiment score of 1.07 beat Genmab A/S's score of 1.03 indicating that Belite Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Belite Bio	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Genmab A/S has a net margin of 21.05% compared to Belite Bio's net margin of 0.00%. Genmab A/S's return on equity of 15.34% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	21.05%	15.34%	8.94%
Belite Bio	N/A	-13.14%	-12.88%

Genmab A/S has a beta of 0.84, suggesting that its stock price is 16% less volatile than the broader market. Comparatively, Belite Bio has a beta of -1.23, suggesting that its stock price is 223% less volatile than the broader market.

Genmab A/S presently has a consensus target price of $39.28, suggesting a potential upside of 36.05%. Belite Bio has a consensus target price of $203.00, suggesting a potential upside of 32.37%. Given Genmab A/S's higher possible upside, equities research analysts plainly believe Genmab A/S is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
Belite Bio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

7.1% of Genmab A/S shares are held by institutional investors. Comparatively, 0.5% of Belite Bio shares are held by institutional investors. 1.5% of Genmab A/S shares are held by insiders. Comparatively, 13.3% of Belite Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Genmab A/S has higher revenue and earnings than Belite Bio. Belite Bio is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.90B	4.61	$963M	$1.32	21.87
Belite Bio	N/A	N/A	-$77.61M	-$2.53	N/A

Summary

Genmab A/S beats Belite Bio on 11 of the 15 factors compared between the two stocks.

How does Belite Bio compare to Ascendis Pharma A/S?

Belite Bio (NASDAQ:BLTE) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation and profitability.

Belite Bio has higher earnings, but lower revenue than Ascendis Pharma A/S. Belite Bio is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$77.61M	-$2.53	N/A
Ascendis Pharma A/S	$814.57M	19.44	-$258M	$8.67	29.28

Ascendis Pharma A/S has a net margin of 57.87% compared to Belite Bio's net margin of 0.00%. Ascendis Pharma A/S's return on equity of 0.00% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-13.14%	-12.88%
Ascendis Pharma A/S	57.87%	N/A	-8.37%

Belite Bio currently has a consensus target price of $203.00, suggesting a potential upside of 32.37%. Ascendis Pharma A/S has a consensus target price of $296.72, suggesting a potential upside of 16.88%. Given Belite Bio's higher probable upside, equities analysts plainly believe Belite Bio is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.05

0.5% of Belite Bio shares are owned by institutional investors. 13.3% of Belite Bio shares are owned by company insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Belite Bio has a beta of -1.23, suggesting that its share price is 223% less volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.37, suggesting that its share price is 63% less volatile than the broader market.

In the previous week, Belite Bio had 1 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 8 mentions for Belite Bio and 7 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 1.27 beat Belite Bio's score of 1.07 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Belite Bio	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascendis Pharma A/S	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Ascendis Pharma A/S beats Belite Bio on 12 of the 16 factors compared between the two stocks.

Get Belite Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BLTE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BLTE vs. The Competition

Export

Metric	Belite Bio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.26B	$3.67B	$6.88B	$12.25B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	-60.62	21.11	27.00	23.71
Price / Sales	N/A	164.10	492.66	73.79
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	7.47	7.88	10.28	6.07
Net Income	-$77.61M	$23.81M	$3.60B	$331.84M
7 Day Performance	2.19%	-3.79%	-1.25%	-1.53%
1 Month Performance	2.36%	-2.59%	-0.35%	-2.46%
1 Year Performance	146.40%	32.85%	18.41%	13.66%

Belite Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BLTE Belite Bio	3.6881 of 5 stars	$153.36 -1.9%	$203.00 +32.4%	+148.0%	$6.26B	N/A	N/A	10	Positive News Analyst Forecast
INSM Insmed	3.8926 of 5 stars	$108.40 -0.7%	$211.00 +94.6%	+3.3%	$23.50B	$606.42M	N/A	1,664	Positive News
BNTX BioNTech	4.1878 of 5 stars	$89.76 -0.3%	$129.13 +43.9%	-22.0%	$22.68B	$3.25B	N/A	7,807
VTRS Viatris	2.5464 of 5 stars	$16.18 -1.3%	$17.50 +8.2%	+84.4%	$18.85B	$14.30B	N/A	30,000	Analyst Upgrade
GMAB Genmab A/S	4.7923 of 5 stars	$28.43 -1.3%	$38.21 +34.4%	+22.2%	$17.72B	$3.72B	21.53	3,029	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BLTE) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Belite Bio (BLTE) Competitors